AAS
GLUE icon

Ameritas Advisory Services’s Monte Rosa Therapeutics GLUE Stock Holding History

Ameritas Advisory Services’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$557 Buy
+23
New +$435 ﹤0.01% 1837

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameritas Advisory Services's GLUE Position: Q2 2026 in Review

Ameritas Advisory Services opened a new position in Monte Rosa Therapeutics (GLUE) in Q2 2026: 23 shares worth $557. The stake represents ﹤0.01% of the portfolio and ranks #1837 among its holdings.

193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Ameritas Advisory Services held 23 shares of Monte Rosa Therapeutics worth $557 as of Q2 2026.
  • Monte Rosa Therapeutics was a new Ameritas Advisory Services position in Q2 2026.
  • Monte Rosa Therapeutics made up ﹤0.01% of Ameritas Advisory Services's portfolio in Q2 2026, its #1837 holding.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Ameritas Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.